Last Updated : May 21, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Duodopa | Levodopa / carbidopa (Drug Plan Submission) | Parkinson's disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Onstryv | safinamide | Parkinson's disease | Do not reimburse | Complete | ||
Neupro | Rotigotine | Parkinson's disease | Do not list | Complete | ||
Duodopa | Levodopa / carbidopa | Parkinson's disease | Do not list | Complete | ||
Azilect | Rasagiline mesylate | Parkinson's disease | N/A | Complete | ||
Azilect | Rasagiline mesylate | Parkinson's disease | Do not list | Complete | ||
Vyalev | foslevodopa foscarbidopa | Parkinson's disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Kynmobi | apomorphine hydrochloride | Parkinson’s Disease | Withdrawn | |||
Kynmobi | apomorphine hydrochloride | Parkinson’s disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Neupro | Rotigotine | Parkinson’s disease | List with clinical criteria and/or conditions | Complete |